Literature DB >> 16551847

Mechanisms underlying the development of androgen-independent prostate cancer.

Kenneth J Pienta1, Deborah Bradley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16551847     DOI： 10.1158/1078-0432.CCR-06-0067

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  158 in total

Review 1.  Novel options for the treatment of castration-resistant prostate cancer.

Authors:  Carsten-H Ohlmann; Axel S Merseburger; Henrik Suttmann; David Schilling; Lutz Trojan; Carsten Kempkensteffen; Stefan Corvin; Michael J Mathers; Patrick J Bastian
Journal:  World J Urol       Date:  2011-11-20       Impact factor: 4.226

2.  Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.

Authors:  Eleanor Jing Yi Cheong; Pramod C Nair; Rebecca Wan Yi Neo; Ho Thanh Tu; Fu Lin; Edmund Chiong; Kesavan Esuvaranathan; Hao Fan; Russell Z Szmulewitz; Cody J Peer; William D Figg; Christina Li Lin Chai; John O Miners; Eric Chun Yong Chan
Journal:  J Pharmacol Exp Ther       Date:  2020-06-17       Impact factor: 4.030

3.  Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.

Authors:  Paula Vainio; Santosh Gupta; Kirsi Ketola; Tuomas Mirtti; John-Patrick Mpindi; Pekka Kohonen; Vidal Fey; Merja Perälä; Frank Smit; Gerald Verhaegh; Jack Schalken; Kalle A Alanen; Olli Kallioniemi; Kristiina Iljin
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

4.  A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.

Authors:  Kern Rei Chng; Cheng Wei Chang; Si Kee Tan; Chong Yang; Shu Zhen Hong; Noel Yan Wei Sng; Edwin Cheung
Journal:  EMBO J       Date:  2012-04-24       Impact factor: 11.598

5.  Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

Authors:  Ashish B Rajput; Melinda A Miller; Alessandro De Luca; Niki Boyd; Sam Leung; Antonio Hurtado-Coll; Ladan Fazli; Edward C Jones; Jodie B Palmer; Martin E Gleave; Michael E Cox; David G Huntsman
Journal:  J Clin Pathol       Date:  2007-01-26       Impact factor: 3.411

Review 6.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Authors:  William P Harris; Elahe A Mostaghel; Peter S Nelson; Bruce Montgomery
Journal:  Nat Clin Pract Urol       Date:  2009-02

Review 7.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

Review 8.  Molecular mechanisms of castration-resistant prostate cancer progression.

Authors:  Smitha S Dutt; Allen C Gao
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

9.  Acid ceramidase as a therapeutic target in metastatic prostate cancer.

Authors:  Luz Camacho; Oscar Meca-Cortés; José Luis Abad; Simón García; Nuria Rubio; Alba Díaz; Toni Celià-Terrassa; Francesca Cingolani; Raquel Bermudo; Pedro L Fernández; Jerónimo Blanco; Antonio Delgado; Josefina Casas; Gemma Fabriàs; Timothy M Thomson
Journal:  J Lipid Res       Date:  2013-02-19       Impact factor: 5.922

10.  CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.

Authors:  Huiying Sun; Sanjay N Mediwala; Adam T Szafran; Michael A Mancini; Marco Marcelli
Journal:  Horm Cancer       Date:  2016-03-08       Impact factor: 3.869
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.